Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Ozanimod Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
2023-510426-33-00Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 36
01
Overview
Phase 3, randomised, double-blind trial of ozanimod in Crohn's disease (3 arms), sponsored by Celgene Corporation. Primary endpoints: Clinical remission at Week 52 (CDAI < 150) and Endoscopic response at Week 52 (SES-CD ≥ 50% decrease). Started Sep 2018; status: completed.
02
Drugs
ozanimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-510426-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510426-33-00.